LIPITOR SUMMARY
LIPITOR is a synthetic lipid-lowering agent. Atorvastatin is an
inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This
enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and
rate-limiting step in cholesterol biosynthesis.
Therapy with lipid-altering agents should be only one component
of multiple risk factor intervention in individuals at significantly increased
risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug
therapy is recommended as an adjunct to diet when the response to a diet
restricted in saturated fat and cholesterol and other nonpharmacologic measures
alone has been inadequate. In patients with CHD or multiple risk factors for
CHD, LIPITOR can be started simultaneously with diet.
Prevention of Cardiovascular Disease
In adult patients without clinically evident coronary heart
disease, but with multiple risk factors for coronary heart disease such as age,
smoking, hypertension, low HDL-C, or a family history of early coronary heart
disease, LIPITOR is indicated to:
- Reduce the risk of myocardial infarction
- Reduce the risk of stroke
- Reduce the risk for revascularization procedures and angina
In patients with type 2 diabetes, and without clinically evident coronary
heart disease, but with multiple risk factors for coronary heart disease such as
retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to:
- Reduce the risk of myocardial infarction
- Reduce the risk of stroke
In patients with clinically evident coronary heart disease, LIPITOR is
indicated to:
- Reduce the risk of non-fatal myocardial infarction
- Reduce the risk of fatal and non-fatal stroke
- Reduce the risk for revascularization procedures
- Reduce the risk of hospitalization for CHF
- Reduce the risk of angina
Hypeerlipidemia
LIPITOR is indicated:
- As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG
levels and to increase HDL-C in patients with primary hypercholesterolemia
(heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb);
- As an adjunct to diet for the treatment of patients with elevated serum TG
levels (Fredrickson Type IV);
- For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to
diet;
- To reduce total-C and LDL-C in patients with homozygous familial
hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL
apheresis) or if such treatments are unavailable;
- As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and
postmenarchal girls, 10 to 17 years of age, with heterozygous familial
hypercholesterolemia if after an adequate trial of diet therapy the following
findings are present:
- LDL-C remains ≥ 190 mg/dL or
- LDL-C remains ≥ 160 mg/dL and:
- there is a positive family history of premature cardiovascular disease
or
- two or more other CVD risk factors are present in the pediatric
patient
Limitations of Use
LIPITOR has not been studied in conditions where the major
lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V).
|
|
NEWS HIGHLIGHTSMedia Articles Related to Lipitor (Atorvastatin)
Does Lipitor Help Rheumatoid Arthritis? Source: MedicineNet Rheumatoid Arthritis Specialty [2017.08.15] Title: Does Lipitor Help Rheumatoid Arthritis? Category: Doctor's & Expert's views on Symptoms Created: 8/15/2017 12:00:00 AM Last Editorial Review: 8/15/2017 12:00:00 AM
Published Studies Related to Lipitor (Atorvastatin)
Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in
atorvastatin trials. [2015] The aim of this study was to evaluate the effect of atorvastatin on lipid
lowering, cardiovascular (CV) events, and adverse events in women compared with
men in 6 clinical trials. In the Incremental Decrease in End Points Through
Aggressive Lipid Lowering (IDEAL) trial (atorvastatin 80 mg vs simvastatin 20 to
40 mg), the Treating to New Targets (TNT) trial (atorvastatin 80 vs 10 mg), the
Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial
(atorvastatin 80 mg vs placebo), and the Collaborative Atorvastatin Diabetes
Study (CARDS), the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), and the
Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in
Non-Insulin-Dependent Diabetes Mellitus (ASPEN) (atorvastatin 10 mg vs placebo),
lipid changes on treatment were compared between genders with studies grouped by
dose...
Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib
administered as monotherapy or in combination with atorvastatin in Japanese
patients with dyslipidemia. [2014] The cholesteryl ester transfer protein (CETP) inhibitor evacetrapib has been
previously shown to increase high-density lipoprotein cholesterol (HDL-C) and
decrease low-density lipoprotein cholesterol (LDL-C) levels, as monotherapy or in
combination with statins... In conclusion, evacetrapib as monotherapy or in combination
with atorvastatin effectively decreased CETP activity and LDL-C levels and
increased HDL-C levels after 12 weeks in Japanese patients with dyslipidemia.
Efficacy of topical atorvastatin for the treatment of pressure ulcers: a
randomized clinical trial. [2014] process of pressure ulcers in critically ill patients... CONCLUSION: Topical application of atorvastatin ointment 1% for 14 days in
Effect of atorvastatin on pancreatic Beta-cell function and insulin resistance in
type 2 diabetes mellitus patients: a randomized pilot study. [2014] type 2 diabetes by using the homeostasis model assessment-2 (HOMA2) index... CONCLUSIONS: Atorvastatin in the dose used failed to produce significant change
Patients with stable coronary artery disease receiving chronic statin treatment
who are undergoing noncardiac emergency surgery benefit from acute atorvastatin
reload. [2014] undergoing noncardiac emergency surgery benefit from acute atorvastatin reload... CONCLUSION: The trial suggests that atorvastatin reload may improve the clinical
Clinical Trials Related to Lipitor (Atorvastatin)
LIpitor and biGuanide to Androgen Delay Trial [Not yet recruiting]
This study is a randomized trial examining the administration of a combination of biguanide
metformin and atorvastatin ("Lipitor") to men who are experiencing rising prostate-specific
antigen (PSA) levels, despite having undergone radical therapy (surgery and/or radiation).
High Dose and Low Dose of Atorvastatin in Patients With Unstable Angina and NSTEMI (Non ST Elevation MI) [Completed]
The aim of this study is to compare the effect of high dose and low dose of Atorvastatin in
reduction level of C-reactive protein (CRP) in patients with unstable angina and NSTEMI (Non
ST Elevation MI) attending Shahid Mohammadi hospital in Bandar Abbas.
A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551) [Completed]
Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia [Completed]
The purpose of this study is to evaluate the efficacy and safety of Omacor (omega-3-acid
ethyl esters) combined with atorvastatin for lowering non-high-density lipoprotein
cholesterol (non-HDL-C) in hypertriglyceridemic subjects.
Atorvastatin for HAART Suboptimal Responders [Completed]
We hypothesise that atorvastatin changes immune activation among HAART-treated adults with
suboptimal cluster cell differentiation 4 (CD4) recovery by 25%
Reports of Suspected Lipitor (Atorvastatin) Side Effects
Myalgia (581),
Death (580),
Myocardial Infarction (379),
Blood Cholesterol Increased (372),
Cerebrovascular Accident (354),
Pain in Extremity (338),
Muscle Spasms (287),
Arthralgia (286),
Pain (279),
Malaise (256), more >>
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 42 ratings/reviews, Lipitor has an overall score of 6.76. The effectiveness score is 7.62 and the side effect score is 7.43. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
| Lipitor review by 44 year old female patient | | Rating |
Overall rating: | | |
Effectiveness: | | Highly Effective |
Side effects: | | No Side Effects | | Treatment Info |
Condition / reason: | | incontinence |
Dosage & duration: | | 4mg taken daily for the period of 3 years - ongoing |
Other conditions: | | continual lack of control over bladder due to chemical imbalance |
Other drugs taken: | | none | | Reported Results |
Benefits: | | regulated bladder control to allow patient (me) to return to a regular life and not have to modify all movements by where the nearest bathroon is located. |
Side effects: | | none |
Comments: | | Single capsule taken in morning. |
|
| Lipitor review by 48 year old female patient | | Rating |
Overall rating: | | |
Effectiveness: | | Considerably Effective |
Side effects: | | No Side Effects | | Treatment Info |
Condition / reason: | | high cholesterol |
Dosage & duration: | | 20mg taken daily for the period of 2 years |
Other conditions: | | none |
Other drugs taken: | | none | | Reported Results |
Benefits: | | lower cholesterol |
Side effects: | | none |
Comments: | | daily with water at nite. and every three month blood test for liver issues. |
|
| Lipitor review by 53 year old female patient | | Rating |
Overall rating: | | |
Effectiveness: | | Ineffective |
Side effects: | | Extremely Severe Side Effects | | Treatment Info |
Condition / reason: | | High Cholesterol |
Dosage & duration: | | 20 mg taken daily for the period of 2 weeks |
Other conditions: | | mitral valve murmer |
Other drugs taken: | | none | | Reported Results |
Benefits: | | I did not take the drug long enough to see any substantial beneficial effects |
Side effects: | | I developed terrible weakness and pain in bilateral knees. I went from being extremely active to being unable to walk up a flight of stairs. It felt as though my knees would crumble under me.By the second week, I could barely walk up more than 3 steps. My doctor took me off the medication immediately, but the effects lasted about 6 months. |
Comments: | | My physician then tried a series of different medications for cholesterol. I was on Crestor, Simvastatin, and Zocor, all with the same side effect. My physician then ordered a lipid blood test to determine if the type of lipid found in my blood would promote cardiac disease, which thank goodness it didn't. I have a family history of elevated cholesterol: all the women in the family are on one of the cholesterol lowering medications: I am the only one in my family that experienced the above side effects. |
|
|
Page last updated: 2017-08-15
|